2019-11-14T11:50:38-06:00 2018-12-31 346565596 ERNST & YOUNG US LLP 18101 VON KARMAN AVENUE SUITE 1700 IRVINE CA 92612 990 2018-01-01 954772979 CALIFORNIA HEART CENTER FOUNDATION CALI 3102488327 8536 WILSHIRE BOULEVARD SUITE 301 BEVERLY HILLS CA 90211 JON KOBASHIGAWA MD PRESIDENT 3102488327 2019-11-14 1 KARA ADAMS P00023315 9497942300 192.231.86.243 2019-11-14 09:48:37 PS P 5D66495798EA847DC80F6602DD5A7F057B72F91F 5D66495798EA847DC80F6602DD5A7F057B72F91F 2018 2020-03-31 21:24:44Z X JON KOBASHIGAWA MD 8536 WILSHIRE BOULEVARD SUITE 301 BEVERLY HILLS CA 90211 1829238 0 X WWW.CALHEART.ORG X 2000 CA PROMOTE & DEVELOP EDUCATIONAL & SCIENTIFIC RESEARCH TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE. 5 3 0 3 0 9008 1466549 1603657 223150 221768 0 0 0 3813 1689699 1829238 0 0 0 0 1388413 1399820 0 0 0 338546 490463 1726959 1890283 -37260 -61045 24693 43775 127865 207993 -103172 -164218 X THE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. 0 0 1669123 225581 THE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. OUR EFFORTS INCLUDE THE PURSUIT OF COLLABORATIVE RESEARCH PROJECTS WHICH PROMOTE A DEEPER UNDERSTANDING OF DISEASE PROGRESSION AND TEST THE EFFICACY OF NEW STRATEGIES FOR DIAGNOSIS AND TREATMENT. AREAS OF RESEARCH CURRENTLY BEING PURSUED INCLUDE NON-INVASIVE METHODS TO DETECT ORGAN REJECTION, NOVEL IMMUNOSUPPRESSIVE AGENTS, IMMUNE MONITORING STRATEGIES, LONG-TERM COMPLICATIONS SUCH AS CARDIAC ALLOGRAFT VASCULOPATHY, (CONTINUED ON SCHEDULE O)(CONTINUATION FROM FORM 990, PAGE 2)NOVEL METHODS FOR ORGAN PROCUREMENT AND PRESERVATION, NEW MECHANICAL CIRCULATORY SUPPORT DEVICES AND PULMONARY HYPERTENSION. THE ORGANIZATION ALSO SUPPORTS IMPORTANT SCIENTIFIC SYMPOSIA, WHICH ALLOW FOR THE EXCHANGE OF IDEAS AMONG LEADERS IN THE FIELD AND PROVIDE A FORUM FOR EXPERTS TO SHARE THEIR EXPERIENCE AND KNOWLEDGE WITH OTHER PRACTITIONERS. THE ORGANIZATION RESOURCES ARE ALSO LEVERAGED TO SUPPORT A SUMMER RESEARCH INTERNSHIP PROGRAM FOR UNDERGRADUATE STUDENTS WITH AN INTEREST IN MEDICINE AND/OR ACADEMIC RESEARCH. FOLLOWING IS A SUMMARY OF PROJECTS AND PROGRAMS IMPLEMENTED IN 2018: SCIENTIFIC FORUMS AND EDUCATIONAL ACTIVITIES:* "CUTTING EDGE OF TRANSPLANTATION (CEOT)" FEBRUARY 8-10TH, 2018THIS CONFERENCE WAS ORGANIZED BY THE AMERICAN SOCIETY OF TRANSPLANTATION, WITH CONTENT DEVELOPED AROUND THE THEMATIC FOCUS OF "BREAKING THROUGH REGULATORY BARRIERS TO UNLEASH TRANSPLANT INNOVATION". DEDICATED HEART AND LUNG SESSIONS WERE DESIGNED, ORGANIZED AND CHAIRED BY DR. KOBASHIGAWA. THE INTERACTIVE SESSIONS ATTRACTED 70+ PARTICIPANTS AND INCLUDED A HIGHLY ACCLAIMED EXPERT FACULTY, A MENTORED CASE STUDY SESSION FOR FELLOWS AND A NETWORKING DINNER.* "CONSENSUS CONFERENCE ON FRAILTY IN SOLID ORGAN TRANSPLANTATION" SUNDAY, FEBRUARY 11TH, 2018 (PHOENIX, AZ)SPONSORED BY THE AMERICAN SOCIETY OF TRANSPLANTATION, THIS CONSENSUS CONFERENCE WAS ORGANIZED AND CHAIRED BY DR. JON KOBASHIGAWA WITH THE GOAL OF PROVIDING A FORUM FOR AN IN-DEPTH DISCUSSION AMONG LEADING EXPERTS IN THE FIELD, INCLUDING CLINICIANS, SURGEONS AND ALLIED HEALTH, ON ISSUES RELATED TO THE ASSESSMENT, DIAGNOSIS, AND TREATMENT OF FRAILTY IN PATIENTS WITH END ORGAN FAILURE. THE CONSENSUS MEETING WAS PRECEDED BY 5 MONTHS OF WORK GROUP CALLS, IN WHICH THE LARGER HEART, LUNG, LIVER AND KIDNEY TRANSPLANT COMMUNITY WERE ENCOURAGED TO PARTICIPATE. FEEDBACK AND DISCUSSIONS FROM THE WORK GROUP CALLS HELPED TO INFORM THE CONSENSUS MEETING OF 28 EXPERTS (7 FROM EACH ORGAN AREA). A MEETING REPORT IS IN THE FINAL STAGES OF PREPARATION AND IS EXPECTED TO BE SUBMITTED TO THE AMERICAN JOURNAL OF TRANSPLANTATION FOR PUBLICATION BY THE END OF AUGUST. * "CONSENSUS CONFERENCE ON CRITICAL CARE IN THORACIC TRANSPLANTATION" SATURDAY, JUNE 2ND, 2018 (SEATTLE, WA)SPONSORED JOINTLY BY THE AST THORACIC AND CRITICAL CARE COMMUNITY OF PRACTICE AND THE CEDARS-SINAI HEART INSTITUTE, THIS CONSENSUS CONFERENCE WAS ORGANIZED AND CHAIRED BY DR JON KOBASHIGAWA AND TOOK PLACE JUST PRIOR TO THE 2018 AMERICAN TRANSPLANT CONGRESS. IT BROUGHT TOGETHER 41 LEADING EXPERTS IN THE FIELD INCLUDING INTENSIVISTS, HOSPITALISTS, CRITICAL CARE NURSES, CARDIOTHORACIC SURGEONS AND TRANSPLANT SPECIALISTS AND PROVIDED A FORUM FOR AN IN-DEPTH DISCUSSION ON CRITICAL CARE. THIS CONFERENCE WAS THE FIRST STEP IN DEVELOPING NEEDED GUIDELINES FOR THE INTERDISCIPLINARY MANAGEMENT OF HEART AND LUNG TRANSPLANT RECIPIENTS IN THE IMMEDIATE POST-OPERATIVE PERIOD, TO IMPROVE OUTCOMES AND MINIMIZE POST-TRANSPLANT COMPLICATIONS. A PUBLICATION OF CONFERENCE RESULTS IS CURRENTLY PENDING. * SUCCESS WITH FAILURE: A MULTIDISCIPLINARY APPROACH TO HEART FAILURE (LOS ANGELES, CA)THIS 1-DAY SYMPOSIUM ON ADVANCED HEART DISEASE WAS HELD ON FRIDAY, MAY 11TH, 2018 AT THE HYATT REGENCY LAX. THIRTY-SIX FACULTY SPEAKERS/MODERATORS COVERED TOPICS RELATED TO THE MANAGEMENT AND TREATMENT OF HEART FAILURE, INTERVENTIONAL PROCEDURES, AND MECHANICAL CIRCULATORY SUPPORT DEVICES AND TRANSPLANTATION AS TREATMENT OPTIONS FOR PATIENTS WITH ADVANCED HEART FAILURE. THE PROGRAM DREW 160 ATTENDEES CONSISTING OF PHYSICIANS, ALLIED HEALTH PROFESSIONALS, INCLUDING NURSE PRACTITIONERS, TRANSPLANT COORDINATORS, PHYSICIAN ASSISTANTS, RNS AND CASE MANAGERS FROM ACROSS SOUTHERN CALIFORNIA. * DSL/THOMAS D. GORDON VISITING PROFESSOR IN ADVANCED HEART DISEASE (LOS ANGELES, CA) THIS VISITING PROFESSORSHIP, HELD OCTOBER 22ND-23RD, 2018, IS ORGANIZED ANNUALLY BY DR. JON KOBASHIGAWA. THIS YEAR'S VISITING PROFESSOR WAS DR. O.H. "BUD" FRAZIER, A TRUE PIONEER IN HEART TRANSPLANTATION AND MECHANICAL CIRCULATORY SUPPORT. HIS TWO-DAY VISIT FROM TEXAS HEART INSTITUTE FEATURED A GRAND ROUNDS LECTURE, A FELLOWS' CASE CONFERENCE, AND A LUNCH LECTURE FOR THE ADVANCED HEART DISEASE CLINICAL TEAMS. DR. FRAZIER SHARED HIS UNIQUE PERSPECTIVE ON THE HISTORY AND EVOLUTION ON MECHANICAL CIRCULATORY SUPPORT. * OPTIMAL CARE AND NEW THERAPIES IN ADVANCED HEART DISEASE (SANTA BARBARA, CA)THIS 1-DAY SYMPOSIUM ON ADVANCED HEART DISEASE TOOK PLACE ON SATURDAY, NOVEMBER 3RD, 2018 AT THE CANARY HOTEL IN SANTA BARBARA. THE PROGRAM FEATURED PRESENTATIONS ON TOPICS RELATED TO THE DIAGNOSIS AND TREATMENT OF HEART FAILURE, TRANSPLANTATION, MECHANICAL CIRCULATORY SUPPORT AND PULMONARY HYPERTENSION. THE PROGRAM WAS ATTENDED BY 41 PARTICIPANTS, INCLUDING A NUMBER OF COMMUNITY CARDIOLOGISTS IN THE LOCAL AREA. * HEART TRANSPLANT PRECEPTORSHIPS: THROUGHOUT THE YEAR, WE RECEIVE REQUESTS TO PROVIDE EXTENDED OBSERVATIONAL TRAINING OPPORTUNITIES TO PHYSICIANS AND ADVANCE PRACTICE NURSES FROM VARIOUS INSTITUTIONS WITH AN INTEREST IN THE MANAGEMENT OF HEART TRANSPLANT AND MECHANICAL ASSIST DEVICE PATIENTS. IN THE LAST YEAR, WE HOSTED THE FOLLOWING VISITING PHYSICIANS:IN-CHEOL KIM, MD, PHD (DONGSAN MEDICAL CENTER, SOUTH KOREA)JONG-CHAN YOUN, MD, PHD (DONGSAN MEDICAL CENTER, SOUTH KOREA)JOANN LINDENFELD, MD (VANDERBILT UNIVERSITY MEDICAL CENTER)KEKI BALSARA, MD (VANDERBILT UNIVERSITY MEDICAL CENTER)KELLY SCHLENDORF, MD, MHS (VANDERBILT UNIVERSITY MEDICAL CENTER)DEONNA MOORE, PHD, MSN (VANDERBILT UNIVERSITY MEDICAL CENTER)EMILY SANDHAUS, RN, BSN (VANDERBILT UNIVERSITY MEDICAL CENTER)PAUL PERRY, MD, PHD (UC DAVIS MEDICAL CENTER)KATHLEEN TONG, MD (UC DAVIS MEDICAL CENTER)ANNETTE NEEDHAM, DNP (UC DAVIS MEDICAL CENTER)MARY ALICE ACKERMAN, ACNP (NORTHWESTERN UNIVERSITY MEDICAL CENTER)PRECEPTORSHIPS GENERALLY TAKE PLACE OVER THE COURSE OF A WEEK, DEPENDING ON THE FOCUS OF THE TRAINING. TRAINING INCLUDES PARTICIPATION IN IN-HOSPITAL ROUNDS, OUT-PATIENT CLINIC VISITS, SURGERY/DEVICE IMPLANTATION OBSERVATIONS, DIDACTIC LECTURES, CASE STUDIES, JOURNAL CLUBS AND RESEARCH MEETINGS.* SUMMER RESEARCH INTERNSHIPS: UNDER THE SUPERVISION AND MENTORSHIP OF DR. JON KOBASHIGAWA, SUMMER HEART TRANSPLANT RESEARCH INTERNSHIPS HAVE BEEN OFFERED TO TEN STUDENTS FOR THE SUMMER OF 2018. THESE INTERNSHIPS PROVIDE STUDENTS AT ALL LEVELS OF TRAINING AN OPPORTUNITY TO LEARN THE CLINICAL RESEARCH PROCESS, INCLUDING MEDICAL LITERATURE REVIEW, STUDY DESIGN, CHART REVIEW/DATA COLLECTION, DATA ANALYSIS, AND ABSTRACT DEVELOPMENT AND SUBMISSION. COMPLETED ABSTRACTS WILL BE SUBMITTED TO THE AMERICAN FEDERATION OF MEDICAL RESEARCH, A FORUM FOR JUNIOR INVESTIGATORS. THIS YEAR'S GROUP INCLUDES STUDENTS FROM:UC IRVINEUC RIVERSIDECAL POLY SAN LUIS OBISPOUC BERKELEYUCLAUNIVERSITY OF SOUTHERN CALIFORNIAROWAN SCHOOL OF OSTEOPATHIC MEDICINE (NJ)MEDICINE IN UNIVERSIDAD ABIERTA INTERAMERICANA* "CURRENT TRENDS IN HEART TRANSPLANTATION: PATIENT EDUCATION SERIES"THIS PATIENT EDUCATION LECTURE BY DR. JON KOBASHIGAWA IS SCHEDULED TWICE A YEAR, COVERING CURRENT TRENDS IN HEART TRANSPLANTATION AND PROVIDING PATIENTS WITH AN OVERVIEW OF CUTTING-EDGE INNOVATIONS IN THE FIELD OF HEART TRANSPLANTATION. FORUMS WERE HELD ON THURSDAY, JUNE 28TH, 2018 AND THURSDAY, DECEMBER 6TH, 2018 AT THE MEDICAL CENTER AND ATTENDED BY POST-TRANSPLANT PATIENTS AS WELL AS PATIENTS ON THE WAITING LIST FOR TRANSPLANTATION. CLINICAL RESEARCH:THIS SECTION IS FORMATTED BY TITLE; PRINCIPAL INVESTIGATOR (PI); STATUS; SPONSOR.A PILOT RANDOMIZED STUDY TO ASSESS THE EFFECT AND SAFETY PROFILE OF THYMOGLOBULIN IN PRIMARY CARDIAC TRANSPLANT RECIPIENTS: A 12-MONTH, SINGLE CENTER, RANDOMIZED OPEN-LABEL STUDY OF EFFICACY COMPARING IMMEDIATE TREATMENT WITH AND WITHOUT THYMOGLOBULIN 1.5MG/KG/D FOR 5 CONSECUTIVE DAYS IN HEART TRANSPLANT RECIPIENTS; KOBASHIGAWA; ENROLLING; SANOFICELL-FREE DNA AND ANTIBODY-MEDIATED REJECTION IN A COHORT OF SENSITIZED HEART TRANSPLANT PATIENTS; KOBASHIGAWA; ENROLLMENT COMPLETE PUBLICATION PENDING; CAREDXDIAGNOSTIC AND THERAPEUTIC APPLICATIONS OF MICROARRAYS IN HEART TRANSPLANTATION, A MULTICENTER STUDY (INTERHEART); KOBASHIGAWA; ENROLLING; UNIVERSITY OF ALBERTA 1669123 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 5 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 X 5 3 0 0 0 0 1 1 1 1 1 0 0 0 1 1 1 0 0 0 1 0 CA X DEBBIE BOTTEN 3104238473 15821 VENTURA BLVD STE 520 ENCINO CA 91436 JON KOBASHIGAWA MD PRESIDENT 2.00 0.00 X X 0 0 0 MICHELE HAMILTON TREASURER 2.00 0.00 X X 0 0 0 THOMAS D GORDON DIRECTOR 1.00 40.00 X 0 71500 -30982 EDUARDO MARBAN MD DIRECTOR 1.00 60.00 X 0 2564875 188978 JAIME MORIGUCHI MD DIRECTOR 2.00 0.00 X 0 0 0 CHRISTINE SUMBI SECRETARY 40.00 0.00 X 0 194786 24007 0 2831161 182003 0 0 1 0 0 1603657 1603657 EDUCATIONAL PROGRAMS 611430 213150 213150 CULTURAL PROGRAMS 611710 8618 8618 221768 RENT REIMBURSMENT 531390 3813 3813 3813 1829238 225581 0 0 197776 197776 1007143 1007143 48755 48755 47132 47132 99014 99014 10380 7266 3114 6680 6012 668 261424 261424 4232 4232 184867 175624 9243 949 949 MEALS AND ENTERTAINMENT 13536 4602 8934 MOVING/STORAGE 2466 2466 DUES & SUBSCRIPTIONS 1996 571 1425 LICENSE & TAXES 1473 1473 2460 2460 1890283 1669123 221160 0 23258 24760 486 19015 107678 107678 949 0 24693 43775 127865 205011 2982 127865 207993 X -103172 -164218 -103172 -164218 24693 43775 X -61045 -1 X 0 0 0 X 1514534 1784016 1531356 1466549 1603657 7900112 1514534 1784016 1531356 1466549 1603657 7900112 7900112 5075 1031 6 0 0 6112 7906224 920705 0.99920 0.99810 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 70594 70594 0 37084 37084 0 0 0 1 0 0 0 0 0 0 0 EDUARDO MARBAN MD DIRECTOR 0 1683109 0 379674 0 502092 0 155682 0 33296 0 2753853 0 0 CHRISTINE SUMBI SECRETARY 0 172038 0 20698 0 2050 0 13740 0 10267 0 218793 0 0 PART I, LINE 3 PLEASE SEE SCHEDULE O NARRATIVE FOR PART VI, SECTION B LINE 15B. PART I, LINE 4B THE PLAN IS A SUPPLEMENTAL RETIREMENT ALLOWANCE THAT IS PAYABLE DIRECTLY TO THE PARTICIPANTS EACH QUARTER. THE BENEFIT FORMULA FOR THIS PLAN HAS ANNUAL CONTRIBUTIONS THAT ARE EITHER A PERCENTAGE OF SALARY, OR ARE DESIGNED TO FUND A PERCENTAGE OF THE ESTIMATED FINAL 5-YEAR AVERAGE SALARY. THE FOLLOWING DIRECTORS RECEIVED PAYMENTS DURING THE YEAR ENDED DECEMBER 31, 2018: CHRISTINE SUMBI 1,492 EDUARDO MARBAN, MD 339,485 FORM 990, PART III, LINE 4A (CONTINUED) OUTCOMES ALLOMAP REGISTRY; KOBASHIGAWA; ENROLLMENT COMPLETE; CAREDX TARGETING INFLAMMATION AND ALLOIMMUNITY IN HEART TRANSPLANT RECIPIENTS WITH TOCILIZUMAB; KOBASHIGAWA; ENROLLING; NIH/MGH RISK FACTORS AND OUTCOMES IN ADVANCED HEART DISEASE (REGISTRY STUDY); KOBASHIGAWA; ENROLLING; INTERNAL KCCQ - QUALITY OF LIFE SURVEY STUDY; KOBASHIGAWA; ENROLLING; INTERNAL MALIGNANCY AFTER HEART TRANSPLANTATION; KOBASHIGAWA/YOUN; PUBLICATION COMPLETE; DONGTAN HOSPITAL, S. KOREA BIOMARKERS OF PRIMARY GRAFT DYSFUNCTION IN CARDIAC TRANSPLANTATION; KOBASHIGAWA; FINAL ANALYSIS PENDING; COLUMBIA UNIVERSITY LONG TERM OUTCOME FOLLOW-UP OF THE RAD001 B253 STUDY, EVEROLIMUS FOR THE PREVENTION OF ALLOGRAFT REJECTION AND VASCULOPATHY IN CARDIAC-TRANSPLANT RECIPIENTS; KOBASHIGAWA; FINAL PUBLICATION PENDING; NOVARTIS CARDIAC SURGERY AFTER HEART TRANSPLANTATION - AN EXPLORATORY, RETROSPECTIVE, MULTICENTER STUDY (CASH-STUDY); KOBASHIGAWA; INTERIM ANALYSIS PENDING; MEDICAL UNIVERSITY OF VIENNA EXTERNAL FACTORS AND OUTCOMES FOR HEART TRANSPLANT RECIPIENTS: A SINGLE CENTER SURVEY STUDY; KOBASHIGAWA; ENROLLING; INTERNAL SURVEILLANCE HEARTCARE OUTCOMES REGISTRY STUDY (SHORE); KOBASHIGAWA; ENROLLING; CAREDX A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY (GALACTIC-HF) ASSESS THE EFFICACY AND SAFETY OF OMECAMTIV MECARBIL ON MORTALITY AND MORBIDITY IN SUBJECTS WITH CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION; CHANG; ENROLLING; AMGEN A DOUBLE-BLIND, RANDOMIZED, SHAM-PROCEDURE-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF ALLOGENEIC MESENCHYMAL PRECURSOR CELLS IN PATIENTS WITH CHRONIC HEART FAILURE DUE TO LEFT VENTRICULAR SYSTOLIC DYSFUNCTION OF EITHER ISCHEMIC OR NON ISCHEMIC ETIOLOGY: DREAM HF-1; CHANG; ENROLLMENT COMPLETE; MESOBLAST,INC. CONTINUED ACCESS PROTOCOL TO COLLECT ADDITIONAL EVIDENCE TO EVALUATE THE SAFETY AND EFFECTIVENESS OF THE PORTABLE ORGAN CARE SYSTEM (OCS) HEART FOR PRESERVING AND ASSESSING EXPANDED CRITERIA DONOR HEARTS FOR TRANSPLANTATION (HEART EXPAND CAP); ESMAILIAN; SITE ACTIVATION; TRANSMEDICS THE FREQUENCY AND SIGNIFICANCE OF BLOOD TYPE A1 DONORS TO NON-A1 SUBGROUP RECIPIENTS IN HEART TRANSPLANTATION; KITTLESON; ENROLLING; INTERNAL TRANSPLANT OF REDEEMED ORGANS BY JUDICIOUS ADMINISTRATION OF NEW DIRECT-ACTING ANTIVIRALS FOR HEPATITIS-C HEART RECIPIENTS (TROJAN-C); KRANSDORF; ENROLLING; BAYLOR UNIVERSITY/ONE LEGACY HEART FAILURE CLINICAL RESEARCH NETWORK ENTRESTO (LCZ696) IN ADVANCED HEART FAILURE (LIFE STUDY); KRANSDORF; ENROLLING; DUKE UNIVERSITY DILATED CARDIOMYOPATHY (DCM) RESEARCH PROJECT; KRANSDORF; ENROLLING; OHIO UNIVERSITY THE DE-NOVO USE OF ECULIZUMAB ALONGSIDE CONVENTIONAL THERAPY IN PRESENSITIZED PATIENTS RECEIVING CARDIAC TRANSPLANTATION: AN OPEN-LABEL, INVESTIGATOR-INITIATED PILOT TRIAL: [THE DUET CARDIAC TRIAL]; PATEL; ENROLLMENT COMPLETE ANALYSIS PENDING; ALEXION MICRORNAS BIOMARKERS OF ALLOGRAFT REJECTION AND CARDIAC ALLOGRAFT VASCULOPATHY; PATEL; ENROLLING; INOVA HEART & VASCULAR INSTITUTE B3461045: A PHASE 3 MULTICENTER, OPEN LABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826-83) 20 MG OR 80 MG [OR TAFAMIDIS (PF-06291826-00) 61 MG] IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (ATTR-CM); PATEL; ENROLLMENT COMPLETE; PFIZER HEART INSTITUTE BIOBANK STUDY; SHAW; ENROLLING; AHA FORM 990, PART IV, LINE 12 THE ORGANIZATION WAS INCLUDED IN A CONSOLIDATED, INDEPENDENT AUDITED FINANCIAL STATEMENTS FOR THE FISCAL YEARS ENDED 6/30/18 AND 6/30/19 DUE TO THE FACT THAT THE TAX YEAR OF ITS TAX-EXEMPT PARENT ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, ENDS ON 6/30. THERE ARE NO AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 12/31/18. FORM 990, PART VI, SECTION A, LINE 6 CEDARS-SINAI MEDICAL CENTER IS THE SOLE CORPORATE MEMBER OF CALIFORNIA HEART CENTER FOUNDATION. FORM 990, PART VI, SECTION A, LINE 7A CEDARS-SINAI MEDICAL CENTER AS THE SOLE CORPORATE MEMBER, CAN ELECT BOARD OF DIRECTORS TO CALIFORNIA HEART CENTER FOUNDATION. FORM 990, PART VI, SECTION A, LINE 7B RESERVED RIGHTS OF CEDARS-SINAI MEDICAL CENTER, THE SOLE CORPORATE MEMBER OF THE ORGANIZATION. THE FOLLOWING ACTIONS MUST BE APPROVED OR ACTED UPON BY CEDARS-SINAI MEDICAL CENTER BEFORE BECOMING EFFECTIVE: (A) ANY SALE OR OTHER DISPOSITION OF ALL OR A SUBSTANTIAL PORTION OF THE ASSETS OF THE ORGANIZATION; (B) ANY MERGER OR AFFILIATION OF THE ORGANIZATION WITH ANY PERSON OR ENTITY OTHER THAN THE MEMBER; (C) ANY AMENDMENT TO THE ARTICLES OF INCORPORATION OR BYLAWS OF THE ORGANIZATION; (D) ANY ACT OR OMISSION WHICH CREATES ANY MATERIAL RISK TO THE MEMBER'S TAX EXEMPT STATUS, OR CREATES ANY MATERIAL RISK OF A VIOLATION OF ANY STATE OR FEDERAL LAWS; (E) DISSOLUTION OF THE ORGANIZATION OR THE FILING OF ANY BANKRUPTCY PETITION; (F) CREATION OF ANY NEW CORPORATION, PARTNERSHIP OR ASSOCIATION; (G) ACQUISITION OF OR THE INVESTMENT IN A NEW OPERATING BUSINESS; (H) ENTERING INTO ANY PARTNERSHIPS OR JOINT VENTURES; (I) ADOPTION OF OR CHANGES TO OPERATING OR CAPITAL BUDGETS; (J) ADOPTION OF THIS CORPORATION'S POLICIES AND PROCEDURES; (K) EXECUTION AND DELIVERY OF ANY NEW AFFILIATION AGREEMENTS AND OTHER RELATIONSHIPS WITH THE UCLA SCHOOL OF MEDICINE AND OTHER INSTITUTIONS OF MEDICAL LEARNING; (L) UNBUDGETED CAPITAL EXPENDITURES OVER $100,000; (M) LOANS, BORROWINGS OR GUARANTEES IN EXCESS OF $100,000, UNLESS APPROVED IN THE BUDGET; (N) ANY SECURITY INTERESTS OR MORTGAGES ON THE PROPERTY OF ORGANIZATION; (O) OPERATING OR CAPITAL LEASES WHERE THE TERM IS OVER FIVE YEARS OR THE TOTAL OBLIGATION UNDER THE LEASE EXCEEDS $100,000, UNLESS APPROVED IN THE BUDGET; (P) TERMINATION OR SELECTION OF THE AUDITORS OF THE ORGANIZATION; (Q) APPOINTMENT OR REMOVAL OF ANY MEMBER OF THE BOARD (OTHER THAN EX-OFFICIO DIRECTORS); (R) APPOINTMENT OF REMOVAL OF ANY OFFICERS; (S) EXECUTION AND DELIVERY OF ANY PROFESSIONAL SERVICE AGREEMENTS; (T) RELOCATION OF PRINCIPAL OFFICE; AND (U) FIXING THE NUMBER OF DIRECTORS OF THE ORGANIZATION. FORM 990, PART VI, SECTION B, LINE 11B THE ORGANIZATION'S FORM 990 UNDERGOES AN INTENSE AND HIGHLY COMPREHENSIVE REVIEW PROCESS. THE REVIEW INVOLVES VARIOUS MANAGEMENT PERSONNEL AND A BIG FOUR ACCOUNTING FIRM. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST POLICY ANNUAL STATEMENTS: EACH DIRECTOR, OFFICER, MEMBER OF A COMMITTEE WITH BOARD-DELEGATED POWERS AND ANY OTHER INTERESTED PERSON AS DETERMINED BY THE BOARD OR COMMITTEE SHALL AT LEAST ANNUALLY SIGN A COPY OF THE "STATEMENT PERTAINING TO CONFLICT OF INTEREST." IF A DIRECTOR, OFFICER, OR COMMITTEE MEMBER, OR DESIGNATED INTERESTED PERSON BECOMES AWARE THAT A POTENTIAL OR APPARENT CONFLICT MAY EXIST WHICH IS NOT DISCLOSED ON SUCH A STATEMENT, IT SHALL BE THE RESPONSIBILITY OF THE INTERESTED PERSON TO DISCLOSE THE POTENTIAL CONFLICT TO THE PRESIDENT AND TO THE BOARD OR APPROPRIATE COMMITTEE AND AS SET FORTH ABOVE, PRIOR TO ANY BOARD OR COMMITTEE DISCUSSIONS OR ACTION WITH RESPECT TO THE RELEVANT TRANSACTION OR ARRANGEMENT, AND, IF RELEVANT, TO LEAVE THE MEETING DURING THE DISCUSSION AND VOTE ON THE TRANSACTION OR ARRANGEMENT. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE RELEVANT CALIFORNIA HEART CENTER FOUNDATION ("CHCF") OFFICER OR ADMINISTRATOR SHALL DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS. IF IT IS DETERMINED THAT A CONFLICT OF INTEREST EXISTS AND, NOTWITHSTANDING THE CONFLICT, THE CHCF OFFICER OR ADMINISTRATOR DETERMINES THAT IT CONTINUES TO BE IN THE BEST INTERESTS OF CHCF TO PROCEED WITH THE TRANSACTION OR ARRANGEMENT AT ISSUE, THE CHCF OFFICER OR ADMINISTRATOR SHALL REFER THE TRANSACTION OR ARRANGEMENT TO THE BOARD OR THE APPROPRIATE BOARD-DESIGNATED COMMITTEE FOR EVALUATION. ALTERNATIVELY IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF THE AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR COMMITTEE MEETING WHILE THE DETERMINATION OF THE EXISTENCE OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR COMMITTEE MEMBERS SHALL DECIDE, BY MAJORITY VOTE, IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: A. AN INTERESTED PERSON MAY MAKE A PRESENTATION TO THE BOARD OR COMMITTEE REGARDING THE TRANSACTION OR ARRANGEMENT. AFTER SUCH PRESENTATION THE INTERESTED PERSON MUST LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON THE TRANSACTION OR ARRANGEMENT. B. THE CHAIR OF THE BOARD OR COMMITTEE SHALL, IF DEEMED APPROPRIATE BY THE BOARD OR COMMITTEE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. C. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER CHCF CAN OBTAIN A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. D. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN CHCF' BEST INTEREST AND FOR ITS OWN BENEFIT AND WHETHER THE TRANSACTION IS FAIR AND REASONABLE TO CHCF AND SHALL MAKE ITS DECISION AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT IN CONFORMITY WITH SUCH DETERMINATION. VIOLATIONS OF THE CONFLICTS POLICY: A. IF THE BOARD OR COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A MEMBER OF THE BOARD OR COMMITTEE OR AN OFFICER OR OTHER INTERESTED PERSON HAS FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL INFORM THE MEMBER OR OFFICER OR INTERESTED PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. B. IF, AFTER HEARING THE RESPONSE OF SUCH PERSON AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. FORM 990, PART VI, SECTION B, LINE 15B THE EXECUTIVE PERSONNEL COMMITTEE (THE COMMITTEE) OF THE TAX-EXEMPT PARENT OF THE ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, IS A STANDING COMMITTEE OF THE BOARD OF DIRECTORS. THE COMMITTEE ADDRESSES COMPENSATION AND BENEFITS REGARDING THE ORGANIZATION'S CHIEF FINANCIAL OFFICER AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER, AND IS AUTHORIZED BY THE BOARD OF DIRECTORS TO ACT ON BEHALF OF THE BOARD WITH RESPECT TO SUCH ISSUES, AND OTHER GOVERNANCE ISSUES AS REQUESTED BY THE BOARD OF DIRECTORS, THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, THE CHAIR OF THE BOARD OF DIRECTORS, OR THE CEO, ALL SUBJECT TO THE COMMITTEE'S ONGOING REPORTING OBLIGATION TO THE BOARD OF DIRECTORS OR THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS. SPECIFICALLY, THE COMMITTEE EVALUATES THE PERFORMANCE AND APPROVES THE COMPENSATION AND BENEFITS FOR THE ORGANIZATION'S CHIEF FINANCIAL OFFICER AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER. THE MEMBERS OF THE COMMITTEE ARE APPOINTED ANNUALLY BY THE CHAIR OF THE MEDICAL CENTER'S BOARD OF DIRECTORS. APPOINTMENTS ARE FOR A ONE YEAR TERM. EACH YEAR, THE COMMITTEE FOLLOWS A PROCESS THAT ENSURES THAT THE COMPENSATION AND BENEFITS IS REASONABLE AND IN COMPLIANCE WITH APPLICABLE LAWS AND REGULATIONS. THE MEDICAL CENTER'S SVP OF HR PROVIDES STAFF SUPPORT TO THE COMMITTEE. THE COMMITTEE MAY INCLUDE MEMBERS OF THE MEDICAL CENTER'S MANAGEMENT TEAM OR ANY OTHER PERSON WHOSE PRESENCE THE COMMITTEE BELIEVES TO BE DESIRABLE OR APPROPRIATE. THE COMMITTEE MAY ENGAGE AN INDEPENDENT COMPENSATION AND BENEFITS CONSULTANT AND ANY OTHER ADVISORS THEY DEEM NECESSARY. THE COMMITTEE MAY ALSO ENGAGE INDEPENDENT COUNSEL. THE MEDICAL CENTER WILL PROVIDE FOR APPROPRIATE FUNDING FOR PAYMENT OF COSTS TO ANY SUCH PERSONS RETAINED BY THE COMMITTEE. ANNUALLY, AT THE COMMITTEE'S DIRECTION, THE INDEPENDENT COMPENSATION CONSULTANT SHALL PREPARE SUCH REPORTS AS THE COMMITTEE REASONABLY DEEMS NECESSARY. AT A MINIMUM, SUCH REPORTS WILL INCLUDE MARKET SURVEY DATA FROM A PEER GROUP DESIGNATED BY THE COMMITTEE, WHICH SHALL BE CONSIDERED BY THE COMMITTEE PRIOR TO MAKING DECISIONS. THE COMMITTEE MEETS AS FREQUENTLY AS THE COMMITTEE DEEMS NECESSARY AND WILL MAINTAIN WRITTEN MINUTES OF ITS MEETING. THE COMPENSATION AND BENEFITS OF THE PRESIDENT AND VICE-PRESIDENT ARE DETERMINED BY THE CHIEF FINANCIAL OFFICER OF THE ORGANIZATION WITH ASSISTANCE FROM HR WHICH PROVIDES AN INDEPENDENT REVIEW OF COMPARABLES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, ITS CONFLICT OF INTEREST POLICY AND ITS TAX-EXEMPT PARENT'S AUDITED FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON WRITTEN REQUEST. FORM 990, PART XI, LINE 9: ROUNDING -1. CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BOULEVARD LOS ANGELES CA 90048 951644600 HEALTHCARE CA 501(C)(3) LINE 3 CEDARS-SINAI HEALTH SYSTEM 0 CEDARS-SINAI MEDICAL CARE FOUNDATION 200 N ROBERTSON BOULEVARD 101 BEVERLY HILLS CA 90211 954457756 PROVISION OF MEDICAL CARE, TEACHING AND RESEARCH CA 501(C)(3) LINE 12A, I CEDARS-SINAI MEDICAL CENTER 1 KERLAN-JOBE ORTHOPAEDIC FOUNDATION 6801 PARK TERRACE LOS ANGELES CA 90045 954707606 EDUCATION AND RESEARCH RELATED TO ORTHOPAEDIC MEDICINE CA 501(C)(3) LINE 7 CEDARS-SINAI MEDICAL CARE FOUNDATION 1 SANTA MONICA ORTHOPAEDIC & SPORTS MED RESEARCH FDN 2020 SANTA MONICA BLVD 4TH FLR SANTA MONICA CA 90404 954789926 EDUCATION AND RESEARCH RELATED TO ORTHOPAEDIC AND NEUROLOGIC CONDITIONS CA 501(C)(3) PF CEDARS-SINAI MEDICAL CARE FOUNDATION 1 CFHS HOLDINGS INC 4650 LINCOLN BLVD MARINA DEL REY CA 90292 201645949 HEALTHCARE CA 501(C)(3) LINE 3 CEDARS-SINAI MEDICAL CENTER 1 CEDARS-SINAI HEALTH SYSTEM 8700 BEVERLY BOULEVARD LOS ANGELES CA 90048 300990905 SUPPORT SPECIFIED NONPROFIT HEALTHCARE ORGANIZATIONS CA 501(C)(3) LINE 12C, III-FI N/A 0 TORRANCE HEALTH ASSOCIATION 3330 LOMITA BLVD TORRANCE CA 90505 330073515 HEALTH SERVICES CA 501(C)(3) LINE 12B, II CEDARS-SINAI HEALTH SYSTEM 1 TORRANCE MEMORIAL MEDICAL CENTER HEALTH CARE FOUNDATION 3330 LOMITA BLVD TORRANCE CA 90505 953528452 FUNDRAISING CA 501(C)(3) LINE 7 TORRANCE HEALTH ASSOCIATION 1 TORRANCE MEMORIAL MEDICAL CENTER 3330 LOMITA BLVD TORRANCE CA 90505 951644042 HEALTH SERVICES CA 501(C)(3) LINE 3 TORRANCE HEALTH ASSOCIATION 1 ENDOSCOPY CENTER OF SANTA MONICA LLC 12400 WILSHIRE BLVD STE 100 LOS ANGELES CA 90025 113652210 ENDOSCOPIES AND RELATED PROCEDURES CA N/A ISS ASC HOLDINGS LLC 27271 LAS RAMBLAS STE 350 MISSION VIEJO CA 92691 471890805 INVESTMENT IN HEALTHCARE SERVICES CA N/A DEL REY SURGERY INVESTORS LLC 11150 SANTA MONICA BLVD STE 700 LOS ANGELES CA 90025 364756208 INVESTMENT IN AMBULATORY SURGERY CENTER DE N/A DEL REY SURGERY CENTER LLC 27271 LAS RAMBLAS STE 350 MISSION VIEJO CA 92691 462305372 OPERATOR OF AMBULATORY SURGERY CENTER CA N/A CEDARS-SINAI BH ASC LLC 200 N ROBERTSON BLVD 101 BEVERLY HILLS CA 90211 812266744 HOLDING COMPANY CA N/A CS-BH ASC HOLDINGS LLC 200 N ROBERTSON BLVD 101 BEVERLY HILLS CA 90211 812246488 HOLDING COMPANY CA N/A INTERNATIONAL SPINE & ORTHOPEDIC INSTITUTE LLC 8500 W 110TH ST OVERLAND PARK KS 66210 263738893 SPINE AND ORTHOPEDIC INSTITUTE DE N/A SANTA MONICA IMAGING GROUP LLC 200 N ROBERTSON BLVD 101 BEVERLY HILLS CA 90211 820760657 IMAGING CENTER CA N/A TORRANCE MEMORIAL SURGICAL CENTER LLC 23560 CRENSHAW BLVD STE 104 TORRANCE CA 90505 465259260 OUTPATIENT SURGICAL SERVICES CA N/A TORRANCE SURGERY CENTER LP 1A BURTON HILLS BLVD NASHVILLE TN 37215 330932093 SURGICAL SERVICES TN N/A 3565 DEL AMO ASSOCIATES 2175 PARK PLACE EL SEGUNDO CA 90245 330554737 RENTAL REAL ESTATE CA N/A OPTIMATRIX HEALTH SOLUTIONS INC 6500 WILSHIRE BLVD 9TH FLR LOS ANGELES CA 90048 954522779 INFORMATION SYSTEMS CA N/A C 1 CENTINELA FREEMAN HOLDINGS INC 4650 LINCOLN BLVD MARINA DEL REY CA 90292 593811890 MEDICAL OFFICE BUILDING AND GROUND LEASE LESSOR CA N/A C 1 OTOHARMONICS CORPORATION 411 SW 6TH AVE PORTLAND OR 97204 461119421 HEALTHCARE PRODUCT DEVELOPMENT DE N/A C 1 0 0 1 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0